322 related articles for article (PubMed ID: 32754277)
1. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse.
Hong HC; Chuang CH; Huang WC; Weng SL; Chen CH; Chang KH; Liao KW; Huang HD
Theranostics; 2020; 10(19):8771-8789. PubMed ID: 32754277
[No Abstract] [Full Text] [Related]
2. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer.
Ouyang M; Li Y; Ye S; Ma J; Lu L; Lv W; Chang G; Li X; Li Q; Wang S; Wang W
PLoS One; 2014; 9(5):e96228. PubMed ID: 24788655
[TBL] [Abstract][Full Text] [Related]
4. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
5. A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.
Turkistani S; Sugita BM; Fadda P; Marchi R; Afsari A; Naab T; Apprey V; Copeland RL; Campbell MC; Cavalli LR; Kanaan Y
BMC Cancer; 2021 Jul; 21(1):861. PubMed ID: 34315420
[TBL] [Abstract][Full Text] [Related]
6. Comparing MicroRNA Profilings of Purified HER-2-Negative and HER-2-Positive Cells Validates miR-362-5p/Sema3A as Characteristic Molecular Change in Triple-Negative Breast Cancers.
Zhang X; He Q; Sun L; Zhang Y; Qin S; Fan J; Wang J
Dis Markers; 2019; 2019():6057280. PubMed ID: 31929841
[TBL] [Abstract][Full Text] [Related]
7. Clinical Identification of Dysregulated Circulating microRNAs and Their Implication in Drug Response in Triple Negative Breast Cancer (TNBC) by Target Gene Network and Meta-Analysis.
Qattan A; Al-Tweigeri T; Alkhayal W; Suleman K; Tulbah A; Amer S
Genes (Basel); 2021 Apr; 12(4):. PubMed ID: 33918859
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation of microRNAs in triple-negative breast cancer.
Paszek S; Gabło N; Barnaś E; Szybka M; Morawiec J; Kołacińska A; Zawlik I
Ginekol Pol; 2017; 88(10):530-536. PubMed ID: 29192413
[TBL] [Abstract][Full Text] [Related]
9. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
[TBL] [Abstract][Full Text] [Related]
10. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
11. Screening protective miRNAs and constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast cancer.
Zhao Y; Song Y; Zhang Y; Ji M; Hou P; Sui F
Mol Cell Probes; 2023 Dec; 72():101940. PubMed ID: 37871689
[TBL] [Abstract][Full Text] [Related]
12. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
13. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients.
Huo D; Clayton WM; Yoshimatsu TF; Chen J; Olopade OI
Oncotarget; 2016 Aug; 7(34):55231-55248. PubMed ID: 27409424
[TBL] [Abstract][Full Text] [Related]
14. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
15. A two-miRNA signature of upregulated miR-185-5p and miR-362-5p as a blood biomarker for breast cancer.
Zhang K; Wang YY; Xu Y; Zhang L; Zhu J; Si PC; Wang YW; Ma R
Pathol Res Pract; 2021 Jun; 222():153458. PubMed ID: 33962174
[TBL] [Abstract][Full Text] [Related]
16. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
17. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling.
Wang DY; Gendoo DMA; Ben-David Y; Woodgett JR; Zacksenhaus E
Breast Cancer Res; 2019 Jan; 21(1):18. PubMed ID: 30704524
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
19. A 4-microRNA signature predicts lymph node metastasis and prognosis in breast cancer.
Chen X; Wang YW; Zhu WJ; Li Y; Liu L; Yin G; Gao P
Hum Pathol; 2018 Jun; 76():122-132. PubMed ID: 29555574
[TBL] [Abstract][Full Text] [Related]
20. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]